RÉSUMÉ
UNLABELLED: The precise role(s) and topological organization of different factors in the hepatitis C virus (HCV) RNA replication complex are not well understood. In order to elucidate the role of viral and host proteins in HCV replication, we have developed a novel in vitro replication system that utilizes a rolling-circle RNA template. Under close-to-physiological salt conditions, HCV NS5BΔ21, an RNA-dependent RNA polymerase, has poor affinity for the RNA template. Human replication protein A (RPA) and HCV NS5A recruit NS5BΔ21 to the template. Subsequently, NS3 is recruited to the replication complex by NS5BΔ21, resulting in RNA synthesis stimulation by helicase. Both RPA and NS5A(S25-C447), but not NS5A(S25-K215), enabled the NS5BΔ21-NS3 helicase complex to be stably associated with the template and synthesize RNA product in a highly processive manner in vitro. This new in vitro HCV replication system is a useful tool that may facilitate the study of other replication factors and aid in the discovery of novel inhibitors of HCV replication. IMPORTANCE: The molecular mechanism of hepatitis C virus (HCV) replication is not fully understood, but viral and host proteins collaborate in this process. Using a rolling-circle RNA template, we have reconstituted an in vitro HCV replication system that allows us to interrogate the role of viral and host proteins in HCV replication and delineate the molecular interactions. We showed that HCV NS5A(S25-C447) and cellular replication protein A (RPA) functionally cooperate as a processivity factor to stimulate HCV replication by HCV NS5BΔ21 polymerase and NS3 helicase. This system paves the way to test other proteins and may be used as an assay for discovery of HCV inhibitors.
Sujet(s)
Hepacivirus/enzymologie , Hepacivirus/physiologie , Interactions hôte-pathogène , Protéine A de réplication/métabolisme , Protéines virales non structurales/métabolisme , Réplication virale , Humains , Protéines mutantes/génétique , Protéines mutantes/métabolisme , Liaison aux protéines , ARN viral/métabolisme , Délétion de séquence , Protéines virales non structurales/génétiqueRÉSUMÉ
BACKGROUND: Direct-acting antiviral (DAAs) agents for hepatitis C virus (HCV) span a variety of targets, including proteins encoded by the NS3/4A, NS4B, NS5A, and NS5B genes. Treatment with DAAs has been shown to select variants with sequence changes in the HCV genome encoding amino acids that may confer resistance to the treatment. In order to assess these effects in patients, a Reverse Transcription Polymerase Chain Reaction (RT-PCR) method was developed to sequence these regions of HCV from patient plasma. METHODS: A method was developed to amplify and sequence genotype 1 HCV RNA from patient plasma. Optimization of HCV RNA isolation, cDNA synthesis, and nested PCR steps were performed. The optimization of HCV RNA isolation, design of RT-PCR primers, optimization of RT-PCR amplification conditions and reagents, and the evaluation of the RT-PCR method performance is described. RESULTS: The optimized method is able to successfully, accurately, and reproducibly amplify near full-length genotype 1 HCV RNA containing a wide range of concentrations (103 to 108 IU/mL) with a success rate of 97%. The lower limit of detection was determined to be 1000 IU/mL HCV RNA. CONCLUSIONS: This assay allows viral sequencing of all regions targeted by the most common DAAs currently in development, as well as the possibility to determine linkage between variants conferring resistance to multiple DAAs used in combination therapy.
Sujet(s)
Génome viral , Hepacivirus/génétique , Biologie moléculaire/méthodes , Réaction de polymérisation en chaîne/méthodes , ARN viral/génétique , RT-PCR/méthodes , Virologie/méthodes , Antiviraux/usage thérapeutique , Résistance virale aux médicaments , Génotype , Hepacivirus/isolement et purification , Hépatite C/traitement médicamenteux , Hépatite C/virologie , Humains , Mutation , Plasma sanguin/virologie , ARN viral/isolement et purification , Analyse de séquence d'ADN/méthodesRÉSUMÉ
Dysregulation of the calcitonin gene-related peptide (CGRP), a potent vasodilator, is directly implicated in the pathogenesis of migraine. CGRP binds to and signals through the CGRP receptor (CGRP-R), a heterodimer containing the calcitonin receptor-like receptor (CLR), a class B GPCR, and RAMP1, a receptor activity-modifying protein. We have solved the crystal structure of the CLR/RAMP1 N-terminal ectodomain heterodimer, revealing how RAMPs bind to and potentially modulate the activities of the CLR GPCR subfamily. We also report the structures of CLR/RAMP1 in complex with the clinical receptor antagonists olcegepant (BIBN4096BS) and telcagepant (MK0974). Both drugs act by blocking access to the peptide-binding cleft at the interface of CLR and RAMP1. These structures illustrate, for the first time, how small molecules bind to and modulate the activity of a class B GPCR, and highlight the challenges of designing potent receptor antagonists for the treatment of migraine and other class B GPCR-related diseases.
Sujet(s)
Azépines/composition chimique , Imidazoles/composition chimique , Pipérazines/composition chimique , Quinazolines/composition chimique , Récepteurs du peptide relié au gène de la calcitonine/composition chimique , Azépines/pharmacologie , Sites de fixation , Peptide relié au gène de la calcitonine/composition chimique , Peptide relié au gène de la calcitonine/métabolisme , Antagonistes du récepteur du peptide relié au gène de la calcitonine , Protéine apparentée au récepteur de la calcitonine/composition chimique , Protéine apparentée au récepteur de la calcitonine/métabolisme , Cristallographie aux rayons X , Imidazoles/pharmacologie , Pipérazines/pharmacologie , Structure tertiaire des protéines , Quinazolines/pharmacologie , Récepteurs du peptide relié au gène de la calcitonine/métabolismeRÉSUMÉ
The calcitonin gene-related peptide (CGRP) receptor is a heterodimer of two membrane proteins: calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1). CLR is a class B G-protein-coupled receptor (GPCR), possessing a characteristic large amino-terminal extracellular domain (ECD) important for ligand recognition and binding. Dimerization of CLR with RAMP1 provides specificity for CGRP versus related agonists. Here we report the expression, purification, and refolding of a soluble form of the CGRP receptor comprising a heterodimer of the CLR and RAMP1 ECDs. The extracellular protein domains corresponding to residues 23-133 of CLR and residues 26-117 of RAMP1 were shown to be sufficient for formation of a stable, monodisperse complex. The binding affinity of the purified ECD complex for the CGRP peptide was significantly lower than that of the native receptor (IC(50) of 12 microM for the purified ECD complex vs 233 pM for membrane-bound CGRP receptor), indicating that other regions of CLR and/or RAMP1 are important for peptide agonist binding. However, high-affinity binding to known potent and specific nonpeptide antagonists of the CGRP receptor, including olcegepant and telcagepant (K(D) < 0.02 muM), as well as N-terminally truncated peptides and peptide analogues (140 nM to 1.62 microM) was observed.
Sujet(s)
Espace extracellulaire/composition chimique , Pliage des protéines , Récepteurs du peptide relié au gène de la calcitonine/composition chimique , Récepteurs à la calcitonine/composition chimique , Séquence d'acides aminés , Fixation compétitive , Protéine apparentée au récepteur de la calcitonine , Lignée cellulaire tumorale , Cristallographie aux rayons X , Dimérisation , Espace extracellulaire/métabolisme , Humains , Protéines et peptides de signalisation intracellulaire/composition chimique , Protéines et peptides de signalisation intracellulaire/métabolisme , Ligands , Structures macromoléculaires/composition chimique , Structures macromoléculaires/métabolisme , Spectroscopie par résonance magnétique , Protéines membranaires/composition chimique , Protéines membranaires/métabolisme , Données de séquences moléculaires , Liaison aux protéines , Structure tertiaire des protéines , Protéine-1 modifiant l'activité des récepteurs , Protéines modifiant l'activité des récepteurs , Récepteurs à la calcitonine/métabolisme , Récepteurs du peptide relié au gène de la calcitonine/biosynthèse , Récepteurs du peptide relié au gène de la calcitonine/génétique , Récepteurs du peptide relié au gène de la calcitonine/isolement et purification , SolubilitéRÉSUMÉ
The cystic fibrosis transmembrane conductance regulator (CFTR) is an anion channel in the ATP-binding cassette (ABC) transporter family. CFTR consists of two transmembrane domains, two nucleotide-binding domains (NBD1 and NBD2), and a regulatory domain. Previous biochemical reports suggest NBD1 is a site of stable nucleotide interaction with low ATPase activity, whereas NBD2 is the site of active ATP hydrolysis. It has also been reported that NBD2 additionally possessed adenylate kinase (AK) activity. Knowledge about the intrinsic biochemical activities of the NBDs is essential to understanding the Cl(-) ion gating mechanism. We find that purified mouse NBD1, human NBD1, and human NBD2 function as adenylate kinases but not as ATPases. AK activity is strictly dependent on the addition of the adenosine monophosphate (AMP) substrate. No liberation of [(33)P]phosphate is observed from the gamma-(33)P-labeled ATP substrate in the presence or absence of AMP. AK activity is intrinsic to both human NBDs, as the Walker A box lysine mutations abolish this activity. At low protein concentration, the NBDs display an initial slower nonlinear phase in AK activity, suggesting that the activity results from homodimerization. Interestingly, the G551D gating mutation has an exaggerated nonlinear phase compared with the wild type and may indicate this mutation affects the ability of NBD1 to dimerize. hNBD1 and hNBD2 mixing experiments resulted in an 8-57-fold synergistic enhancement in AK activity suggesting heterodimer formation, which supports a common theme in ABC transporter models. A CFTR gating mechanism model based on adenylate kinase activity is proposed.
Sujet(s)
Adénosine triphosphate/métabolisme , Adenylate kinase/métabolisme , Protéine CFTR/composition chimique , Nucléotides/métabolisme , Adenosine triphosphatases/métabolisme , Adenylate kinase/antagonistes et inhibiteurs , Animaux , Sites de fixation , Catalyse , Chlorures/métabolisme , Protéine CFTR/physiologie , Dimérisation , Humains , Hydrolyse , Transport des ions , SourisRÉSUMÉ
Topoisomerase IV and DNA gyrase are related bacterial type II topoisomerases that utilize the free energy from ATP hydrolysis to catalyze topological changes in the bacterial genome. The essential function of DNA gyrase is the introduction of negative DNA supercoils into the genome, whereas the essential function of topoisomerase IV is to decatenate daughter chromosomes following replication. Here, we report the crystal structures of a 43-kDa N-terminal fragment of Escherichia coli topoisomerase IV ParE subunit complexed with adenylyl-imidodiphosphate at 2.0-A resolution and a 24-kDa N-terminal fragment of the ParE subunit complexed with novobiocin at 2.1-A resolution. The solved ParE structures are strikingly similar to the known gyrase B (GyrB) subunit structures. We also identified single-position equivalent amino acid residues in ParE (M74) and in GyrB (I78) that, when exchanged, increased the potency of novobiocin against topoisomerase IV by nearly 20-fold (to 12 nM). The corresponding exchange in gyrase (I78 M) yielded a 20-fold decrease in the potency of novobiocin (to 1.0 micro M). These data offer an explanation for the observation that novobiocin is significantly less potent against topoisomerase IV than against DNA gyrase. Additionally, the enzyme kinetic parameters were affected. In gyrase, the ATP K(m) increased approximately 5-fold and the V(max) decreased approximately 30%. In contrast, the topoisomerase IV ATP K(m) decreased by a factor of 6, and the V(max) increased approximately 2-fold from the wild-type values. These data demonstrate that the ParE M74 and GyrB I78 side chains impart opposite effects on the enzyme's substrate affinity and catalytic efficiency.
Sujet(s)
Antibactériens/pharmacologie , DNA topoisomerase IV/antagonistes et inhibiteurs , DNA topoisomerase IV/composition chimique , Escherichia coli/enzymologie , Novobiocine/pharmacologie , Inhibiteurs de la topoisomérase-II , Adenosine triphosphatases/métabolisme , Adénosine triphosphate/métabolisme , Clonage moléculaire , Cristallographie aux rayons X , DNA topoisomerase IV/génétique , Résistance bactérienne aux médicaments , Cinétique , Modèles moléculaires , Conformation des protéines , Protéines recombinantes/métabolisme , Relation structure-activitéRÉSUMÉ
FLT3 is a type III receptor tyrosine kinase that is thought to play a key role in hematopoiesis. Certain classes of FLT3 mutations cause constitutively activated forms of the receptor that are found in significant numbers of patients with acute myelogenous leukemia (AML). The mutations occur either in the activation loop, for example, as point mutations of Asp835 or as internal tandem duplication (ITD) sequences in the juxtamembrane (JM) domain. To further understand the nature of FLT3 autoinhibition and regulation, we have determined the crystal structure of the autoinhibited form of FLT3. This structure shows the autoinhibitory conformation of a complete JM domain in this class of receptor tyrosine kinases. The detailed inhibitory mechanism of the JM domain is revealed, which is likely utilized by other members of type III receptor tyrosine kinases.
Sujet(s)
Protéines proto-oncogènes/composition chimique , Protéines proto-oncogènes/physiologie , Récepteurs à activité tyrosine kinase/composition chimique , Récepteurs à activité tyrosine kinase/physiologie , Séquence d'acides aminés , Animaux , Sites de fixation , Clonage moléculaire , Banque de gènes , Humains , Modèles moléculaires , Données de séquences moléculaires , Mutation , Mutation ponctuelle , Conformation des protéines , Structure secondaire des protéines , Structure tertiaire des protéines , Similitude de séquences d'acides aminés , Tyrosine kinase-3 de type fmsRÉSUMÉ
Aurora-2 is a key member of a closely related subgroup of serine/threonine kinases that plays important roles in the completion of essential mitotic events. Aurora-2 is oncogenic and amplified in various human cancers and could be an important therapeutic target for inhibitory molecules that would disrupt the cell cycle and block proliferation. We report the first crystal structure of Aurora-2 kinase in complex with adenosine. Analysis of residues in the active site suggests differences with structurally and biologically related protein kinases. The activation loop, which contains residues specific to the Aurora family of kinases, has a unique conformation. These results provide valuable insight into the design of selective and highly potent ATP-competitive inhibitors of the Aurora kinases.
Sujet(s)
Protein-Serine-Threonine Kinases/composition chimique , Aurora kinases , Sites de fixation , Cristallographie aux rayons X , Humains , Modèles moléculaires , Tumeurs/enzymologie , Conformation des protéines , Structure secondaire des protéines , Protéines recombinantes/composition chimique , Délétion de séquenceRÉSUMÉ
MAPK-activated protein kinase 2 (MAPKAPK2), one of several kinases directly phosphorylated and activated by p38 MAPK, plays a central role in the inflammatory response. The activated MAPKAPK2 phosphorylates its nuclear targets CREB/ATF1, serum response factor, and E2A protein E47 and its cytoplasmic targets HSP25/27, LSP-1, 5-lipoxygenase, glycogen synthase, and tyrosine hydroxylase. The crystal structure of unphosphorylated MAPKAPK2, determined at 2.8 A resolution, includes the kinase domain and the C-terminal regulatory domain. Although the protein is inactive, the kinase domain adopts an active conformation with aspartate 366 mimicking the missing phosphorylated threonine 222 in the activation loop. The C-terminal regulatory domain forms a helix-turn-helix plus a long strand. Phosphorylation of threonine 334, which is located between the kinase domain and the C-terminal regulatory domain, may serve as a switch for MAPKAPK2 nuclear import and export. Phosphorylated MAPKAPK2 masks the nuclear localization signal at its C terminus by binding to p38. It unmasks the nuclear export signal, which is part of the second C-terminal helix packed along the surface of kinase domain C-lobe, and thereby carries p38 to the cytoplasm.